Generate Biomedicines, Inc.

Generate Biomedicines, Inc. is a biotechnology company based in Somerville, Massachusetts, incorporated in 2018. The company specializes in generative biology, applying machine learning to discover and develop new protein therapeutics in the United States. It focuses on programming novel protein therapeutics using protein-based modalities. Key product candidates include GB-0895, an investigational long-acting anti-TSLP monoclonal antibody for severe asthma, intended for every six-month dosing. Other candidates are GB-4362, an MMAE payload neutralizer monoclonal antibody, and GB-5267, a MUC16 CAR-T Cell therapy. The company also develops the Generate Platform, designed as a therapeutic area and protein modality agnostic system. This platform integrates computational innovation with scalable biohardware to address therapeutic challenges that traditional technologies cannot. The company changed its name from Generate Biologics, Inc. to Generate Biomedicines, Inc. in February 2020.